Skip to main content

Table 4 Adjusted relative odds of albuminuria, microalbuminuria, and macroalbuminuria for Enh 2 in all genotyped European Americans and African Americans, by type 2 diabetes status.

From: Genetic variation of Glucose Transporter-1 (GLUT1) and albuminuria in 10,278 European Americans and African Americans: a case-control study in the Atherosclerosis Risk in Communities (ARIC) Study

 

GLUT1 Enh2Risk Genotype(TT) Relative Odds (95% Confidence Interval) reference: (CC or CT)

Model† (N = Enh2 TT Genotype/All Genotypes)

ALBUMINURIA (N Cases = Cases with Enh2 TT Genotype/All Cases)

MICROALBUMINURIA (N Cases = Cases with Enh2 TT Genotype/All Cases)

MACROALBUMINURIA (N Cases = Cases with Enh2 TT Genotype/All Cases)

EUROPEAN AMERICANS

OR (95% CI)

P-Value

OR (95% CI)

P-Value

OR (95% CI)

P-Value

   TYPE 2 DIABETES (N = 72/1,095)

(N Cases = 20/187)

(N Cases = 14/134)

(N Cases = 6/53)

Model 1

2.11 (1.19 - 3.73) *

0.010

2.01 (1.06 - 3.82) *

0.034

2.69 (1.02 - 7.09) *

0.045

Model 2

2.14 (1.20 - 3.80) **

0.009

2.00 (1.05 - 3.81) *

0.035

2.66 (0.98 - 7.26)

0.056

Model 2 + Fasting Glucose§

1.99 (1.07 - 3.68) *

0.029

2.07 (1.06 - 4.06) *

0.034

1.85 (0.58 - 5.91)

0.299

   NON-DIABETIC (N = 478/7,027)

(N Cases = 24/344)

(N Cases = 19/298)

(N Cases = 5/46)

Model 1

1.01 (0.65 - 1.55)

0.980

0.91 (0.56 - 1.48)

0.713

1.64 (0.64 - 4.25)

0.305

Model 2

1.03 (0.67 - 1.59)

0.899

0.93 (0.57 - 1.50)

0.764

1.77 (0.67 - 4.64)

0.246

Model 2 + Fasting Glucose§

1.05 (0.68 - 1.63)

0.815

0.95 (0.59 - 1.54)

0.843

1.78 (0.68 - 4.66)

0.242

AFRICAN AMERCIANS

OR (95% CI)

P-Value

OR (95% CI)

P-Value

  

   TYPE 2 DIABETES (N = 2/573)

(N Cases = 1/160)

(N Cases = 1/107)

(N Cases = 0/53)

Model 1

3.09 (0.18 - 54.14)

0.440

5.37 (0.32 - 90.91)

0.244

  

Model 2

4.36 (0.24 - 79.81)

0.321

6.39 (0.37 - 110.75)

0.203

  

Model 2 + Fasting Glucose§

7.26 (0.38 - 137.93)

0.187

8.12 (0.44 - 148.09)

0.158

  

   NON-DIABETIC (N = 4/1583)

(N Cases = 1/134)

(N Cases = 1/113)

(N Cases = 0/21)

Model 1

3.29 (0.33 - 32.84)

0.310

4.14 (0.41 - 41.44)

0.227

  

Model 2

4.69 (0.47 - 46.58)

0.187

5.15 (0.51 - 51.66)

0.164

  

Model 2 + Fasting Glucose

8.07 (0.70 - 93.63)

0.095

8.60 (0.73 - 100.97)

0.087

  
  1. Statistical significance of point estimates: * P < .05 | ** P < .01 | *** P < .001
  2. † Analyses with microalbuminuria as the outcome excluded macroalbuminuria cases. Analyses with macroalbuminuria as the outcome excluded microalbuminuria cases. Among African Americans, analyses with macroalbuminuria were omitted due to extremely low allele frequency.
  3. Model 1 includes age, sex, systolic blood pressure, diastolic blood pressure and hypertension medication use.
  4. Model 2 includes Model 1 covariates and BMI and estimated glomerular filtration rate.
  5. § Model 2 + Fasting Glucose is limited to individuals with fasting glucose values: non-diabetic European Americans N = 6,927 (340 albuminuria cases) and European Americans with type 2 diabetes N = 983 (166 albuminuria cases) and non-diabetic blacks N = 1,520 (126 albuminuria cases) and blacks with type 2 diabetes N = 415 (100 albuminuria cases).
  6. Among European Americans, P-values estimating interaction between GLUT Enh2 and diabetes were not significant for the outcomes of albuminuria (P-interaction = 0.064), microalbuminuria (P-interaction = 0.071), and macroalbuminuria (P-interaction = 0.730). Among blacks, P-values estimating interaction between GLUT Enh2 and diabetes were not significant for the outcomes of albuminuria (P-interaction = 0.86), microalbuminuria (P-interaction = 0.96).
Back to article page

BMC Medical Genetics

ISSN: 1471-2350

Contact us